SCHEMBL295141

SCHEMBL295141

[O]S(=O)(=O)Cc1cccc2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.53
CYP1A2 P05177 3/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2C9 P11712 1/20 0.50
NQO2 P16083 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
ACP3 P15309 1/20 0.48
CYP2D6 P10635 2/20 0.47
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
CA1 P00915 1/20 0.44
CA9 Q16790 1/20 0.44
GAA P10253 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MTNR1A P48039 1/20 0.42
CTNNB1 P35222 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8109577 0.85 CA2 (0.55) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL40373 0.83 TDP1 (0.55) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL3245793 0.82 NQO2 (0.57) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL5507285 0.82 CA2 (0.61) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL30532459 0.82 TDP1 (0.53) CA2CYP1A2CYP2C19CYP2C9NQO2
Naphthalene SCHEMBL9470169 0.82 TDP1 (0.53) CA2CYP1A2CYP2C19CYP2C9NQO2
Ammonia Solution, Strong SCHEMBL10719436 0.82 TDP1 (0.53) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL5507279 0.82 CA2 (0.51) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL10983690 0.79 TDP1 (0.50) CA2CYP1A2CYP2C19CYP2C9NQO2
SCHEMBL3248982 0.77 NQO2 (0.49) CA2CYP1A2CYP2C19CYP2C9NQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0255134-B1 CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP claimed
EP-0164298-A2 6-Alpha-methyl-D-homo-corticoids SCHERING AKTIENGESELLSCHAFT (DE) 1985-12-11 EP claimed
EP-4400492-A1 ACRIDINE COMPOUND OSAKA UNIVERSITY (JP) 2024-07-17 EP disclosed
US-20240208999-A1 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-06-27 US disclosed
CN-118103359-A Preparation method of eribulin derivative 江苏恒瑞医药股份有限公司 2024-05-28 CN disclosed
EP-4370507-A1 HYDROGENATED QUINOXALINES Otsuka Pharmaceutical Co., Ltd. (JP) 2024-05-22 EP disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
CN-117940408-A Acridine compounds 国立大学法人大阪大学 2024-04-26 CN disclosed
US-20240132518-A1 CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PREPARATION METHOD THEREFOR SHANGHAI SENHUI MEDICINE CO., LTD. (CN) 2024-04-25 US disclosed
EP-4347597-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS Otsuka Pharmaceutical Co., Ltd. (JP) 2024-04-10 EP disclosed
US-20240109842-A1 ACRYLAMIDE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-04-04 US disclosed
US-4594347-A MICROBIOCIDES OTSUKA PHARMACEUTICAL CO. LIMITED (JP) 1986-06-10 US disclosed
EP-0168003-A1 Oxindol compounds, compositions containing same and processes for preparing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-01-15 EP disclosed
US-4514401-A CARDIOTONICS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1985-04-30 US disclosed
US-4487772-A CARDIOTONIC AGENTS OTSUKA PHARMACEUTICAL CO. LTD. (JP) 1984-12-11 US disclosed
US-4468402-A Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-08-28 US disclosed
EP-0115334-A1 Benzo-heterocyclic compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-08-08 EP disclosed
US-4454130-A CARDIOTONIC, HYPOTENSIVE AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-06-12 US disclosed
US-4435404-A ANTICOAGULANTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-03-06 US disclosed
US-4415572-A CARDIOTONIC AND INOTROPIC AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132518-A1 CEPHALOSPORIN ANTIBACTERIAL COMPOUND AND PREPARATION METHOD THEREFOR WASF2, MRPL21, CLSPN CA2 4379/4885CYP1A2 1800/4885CYP2C19 415/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A CA2 44/4885CYP1A2 35/4885CYP2C19 31/4885
US-20240109842-A1 ACRYLAMIDE COMPOUNDS HPGDS, MYADM, ACR CA2 4808/4885CYP1A2 888/4885CYP2C19 635/4885
US-20240208999-A1 HETEROCYCLIC COMPOUND AHR, PDGFRA, PDGFRB CA2 3916/4885CYP1A2 175/4885CYP2C19 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.